Loading...

Immutep

DB:YP1A
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YP1A
DB
A$91M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • Immutep has significant price volatility in the past 3 months.
YP1A Share Price and Events
7 Day Returns
-6.3%
DB:YP1A
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
10.1%
DB:YP1A
-10.2%
DE Biotechs
-6%
DE Market
YP1A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Immutep (YP1A) -6.3% -40.3% -13.3% 10.1% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • YP1A outperformed the Biotechs industry which returned -10.2% over the past year.
  • YP1A outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
YP1A
Industry
5yr Volatility vs Market

Value

 Is Immutep undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Immutep to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Immutep.

DB:YP1A Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:YP1A
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 30%) (7.82%))
1.353
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.35
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.353 * 5.96%)
8.29%

Discounted Cash Flow Calculation for DB:YP1A using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Immutep is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:YP1A DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 8.29%)
2019 -13.58 Analyst x1 -12.54
2020 -12.81 Analyst x1 -10.92
2021 -15.56 Analyst x1 -12.25
2022 -0.44 Analyst x1 -0.32
2023 129.70 Analyst x1 87.09
2024 231.27 Est @ 78.31% 143.40
2025 358.21 Est @ 54.89% 205.10
2026 496.09 Est @ 38.49% 262.29
2027 630.08 Est @ 27.01% 307.63
2028 749.64 Est @ 18.98% 337.97
Present value of next 10 years cash flows A$1,307.44
DB:YP1A DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$749.64 × (1 + 0.23%) ÷ (8.29% – 0.23%)
A$9,317.17
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$9,317.17 ÷ (1 + 8.29%)10
A$4,200.63
DB:YP1A Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$1,307.44 + A$4,200.63
A$5,508.07
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$5,508.07 / 3,383.60
A$1.63
DB:YP1A Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:YP1A represents 60.38647x of ASX:IMM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
60.38647x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (AUD) x Listing Adjustment Factor
= A$ 1.63 x 60.38647
€98.30
Value per share (EUR) From above. €98.30
Current discount Discount to share price of €1.63
= -1 x (€1.63 - €98.30) / €98.30
98.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Immutep is available for.
Intrinsic value
>50%
Share price is €1.63 vs Future cash flow value of €98.3
Current Discount Checks
For Immutep to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Immutep's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Immutep's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Immutep's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Immutep's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:YP1A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.01
ASX:IMM Share Price ** ASX (2019-04-18) in AUD A$0.03
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Immutep.

DB:YP1A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:IMM Share Price ÷ EPS (both in AUD)

= 0.03 ÷ -0.01

-4.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immutep is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Immutep is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Immutep's expected growth come at a high price?
Raw Data
DB:YP1A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
83.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Immutep, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Immutep's assets?
Raw Data
DB:YP1A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.01
ASX:IMM Share Price * ASX (2019-04-18) in AUD A$0.03
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:YP1A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:IMM Share Price ÷ Book Value per Share (both in AUD)

= 0.03 ÷ 0.01

2.69x

* Primary Listing of Immutep.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immutep is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Immutep's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Immutep has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Immutep expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
83.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Immutep expected to grow at an attractive rate?
  • Immutep's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Immutep's earnings growth is expected to exceed the Germany market average.
  • Immutep's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:YP1A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:YP1A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 83.9%
DB:YP1A Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 23.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:YP1A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:YP1A Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 38 69 107 1
2022-06-30 26 0 14 1
2021-06-30 19 -11 -9 1
2020-06-30 48 5 -18 1
2019-06-30 8 21 -9 1
DB:YP1A Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 5 -10 -17
2018-09-30 6 -9 -15
2018-06-30 7 -8 -13
2018-03-31 6 -8 -12
2017-12-31 7 -8 -10
2017-09-30 5 -8 -9
2017-06-30 4 -9 -9
2017-03-31 3 -8 -10
2016-12-31 2 -9 -10
2016-09-30 2 -10 -36
2016-06-30 2 -11 -62
2016-03-31 2 -10 -71

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Immutep's earnings are expected to grow significantly at over 20% yearly.
  • Immutep's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:YP1A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Immutep Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YP1A Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 0.03 0.05 0.00 2.00
2022-06-30 0.01 0.01 0.00 2.00
2021-06-30 -0.01 0.00 -0.01 2.00
2020-06-30 0.00 0.01 -0.01 3.00
2019-06-30 -0.01 0.00 -0.01 3.00
DB:YP1A Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 -0.02
2016-06-30 -0.03
2016-03-31 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Immutep will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Immutep's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Immutep has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Immutep performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Immutep's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Immutep does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Immutep's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Immutep's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Immutep's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Immutep Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YP1A Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.90 -17.10 6.50
2018-09-30 5.88 -14.92 6.87
2018-06-30 6.85 -12.75 7.24
2018-03-31 6.37 -11.61 6.58
2017-12-31 6.76 -9.63 6.23
2017-09-30 5.44 -9.50 5.29
2017-06-30 4.12 -9.37 4.35
2017-03-31 3.49 -9.81 5.20
2016-12-31 2.09 -10.06 4.92
2016-09-30 1.93 -36.04 29.68
2016-06-30 1.76 -62.02 54.45
2016-03-31 1.65 -71.37 53.98
2015-12-31 1.43 -81.77 54.34
2015-09-30 1.38 -56.96 30.03
2015-06-30 1.34 -32.15 5.72
2015-03-31 1.39 -22.97 5.32
2014-12-31 1.45 -13.79 4.91
2014-09-30 1.73 -13.57 4.50
2014-06-30 2.02 -13.34 4.09
2014-03-31 1.96 -13.25 4.39
2013-12-31 1.90 -13.15 4.69
2013-09-30 1.78 -14.19 4.77
2013-06-30 1.65 -15.23 4.85
2013-03-31 1.58 -16.94 4.96
2012-12-31 1.52 -18.66 5.07
2012-09-30 1.52 -19.30 5.52
2012-06-30 1.52 -19.94 5.98

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Immutep has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Immutep has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Immutep improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Immutep's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Immutep has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Immutep's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Immutep's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Immutep is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Immutep's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Immutep's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Immutep Company Filings, last reported 3 months ago.

DB:YP1A Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 33.53 7.14 26.00
2018-09-30 33.53 7.14 26.00
2018-06-30 33.52 6.65 23.48
2018-03-31 33.52 6.65 23.48
2017-12-31 27.13 6.21 13.70
2017-09-30 27.13 6.21 13.70
2017-06-30 26.53 5.78 12.24
2017-03-31 28.46 5.59 13.88
2016-12-31 31.25 5.40 16.57
2016-09-30 31.25 5.40 16.57
2016-06-30 35.32 5.03 20.88
2016-03-31
2015-12-31 40.52 4.70 25.48
2015-09-30 40.52 4.70 25.48
2015-06-30 24.69 1.51 6.76
2015-03-31 24.69 1.51 6.76
2014-12-31 22.97 3.50 5.73
2014-09-30 22.97 3.50 5.73
2014-06-30 22.59 0.00 23.20
2014-03-31 22.59 0.00 23.20
2013-12-31 30.01 0.00 28.58
2013-09-30 30.01 0.00 28.58
2013-06-30 29.25 0.00 30.02
2013-03-31 29.25 0.00 30.02
2012-12-31 29.36 0.00 28.09
2012-09-30 29.36 0.00 28.09
2012-06-30 37.16 0.00 38.04
  • Immutep's level of debt (21.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 21.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Immutep has sufficient cash runway for 2.6 years based on current free cash flow.
  • Immutep has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of -3.1% each year.
X
Financial health checks
We assess Immutep's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Immutep has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Immutep's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Immutep dividends. Estimated to be 0% next year.
If you bought €2,000 of Immutep shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Immutep's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Immutep's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:YP1A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:YP1A Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30
2021-06-30
2020-06-30 0.00 1.00
2019-06-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Immutep has not reported any payouts.
  • Unable to verify if Immutep's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Immutep's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Immutep has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Immutep's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Immutep's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Immutep afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Immutep has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Immutep's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marc Voigt
COMPENSATION A$1,339,127
AGE 45
TENURE AS CEO 4.8 years
CEO Bio

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been the Chief Financial Officer and Chief Operating Officer at caprotec bioanalytics GmbH since joining on July 12, 2011 and serves as its Managing Director. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He serves as the Chief Financial Officer of Immutep Limited since November, 2012 and serves as its Chief Business Officer since May 2012. Mr. Voigt served as a General Manager of The European Operations at Immutep Limited since July 9, 2014. Mr. Voigt has more than 14 years of experience in the corporate and biotechnology sectors. He served as General Manager of German Subsidiary of Immutep Limited since May 2012. He joined Immutep’s management team in 2011 as the General Manager of Prima’s European operations at Prima BioMed GmbH. He has held management positions in a number of biotech and technology investment companies in Europe. He served as Executive Officer of Heidelberger Beteiligungsholding AG. He joined caprotec bioanalytics GmbH from Medical Enzymes AG (New Medical Enzymes AG), where he served as the Chief Financial Officer and Chief Business Officer. He served as the Chief Financial Officer and Chief Business Officer at Revotar Biopharmaceuticals AG. Prior to that, he served as an Investment Manager at Mediport Venture GmbH and Mediport Ventures Fund. Before that, Mr. Voigt worked in business development and managed IPOs for the investment bank net.IPO.AG in Frankfurt. He served as an investment manager for Allianz Insurance biotech venture fund and as a personal assistant to a member of the Executive Board of Allianz Insurance. Mr. Voigt has also worked for German investment bank, net.IPO.AG, in the area of business development and German securities offerings. He served as a Member of the Supervisory Board of Elanix Biotechnologies AG till 2019. He is a Member of the pharma licensing club Germany and a Member of the judging panel of Germany's largest business plan competition. Mr. Voigt earned a Master’s Degree in Business Administration from the Freie Universitat of Berlin.

CEO Compensation
  • Marc's compensation has increased whilst company is loss making.
  • Marc's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Immutep management team in years:

2.4
Average Tenure
45
Average Age
  • The tenure for the Immutep management team is about average.
Management Team

Marc Voigt

TITLE
Executive Director
COMPENSATION
A$1M
AGE
45
TENURE
4.8 yrs

Deanne Miller

TITLE
COO, General Counsel & Company Secretary
COMPENSATION
A$721K
AGE
41
TENURE
2.4 yrs

Frédéric Triebel

TITLE
Chief Scientific Officer & Chief Medical Officer
COMPENSATION
A$786K
AGE
63
TENURE
4.3 yrs

Jay Campbell

TITLE
Chief Business Officer and VP of Business Development & Investor Relations
TENURE
1.6 yrs

David Fang

TITLE
Finance Director & Assistant Company Secretary
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Immutep board of directors in years:

1.8
Average Tenure
47.5
Average Age
  • The average tenure for the Immutep board of directors is less than 3 years, this suggests a new board.
Board of Directors

Russell Howard

TITLE
Non-Executive Chairman
COMPENSATION
A$90K
AGE
68
TENURE
1.4 yrs

Marc Voigt

TITLE
Executive Director
COMPENSATION
A$1M
AGE
45
TENURE
4.8 yrs

Pete Meyers

TITLE
Non-Executive Deputy Chairman
COMPENSATION
A$136K
AGE
48
TENURE
1.4 yrs

Martine Piccart

TITLE
Chairman of Clinical Advisory Board
TENURE
1.8 yrs

David Cameron

TITLE
Member of Clinical Advisory Board
TENURE
1.8 yrs

Luc Dirix

TITLE
Member of Clinical Advisory Board
TENURE
1.8 yrs

Samson Fung

TITLE
Member of Clinical Advisory Board
TENURE
1.8 yrs

Salah-Eddin Al-Batran

TITLE
Member of Clinical Advisory Board
TENURE
1.8 yrs

Grant Chamberlain

TITLE
Non-Executive Director
COMPENSATION
A$138K
AGE
47
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Mar 19 Sell Altium Capital Management LP Company 07. Jan 19 22. Mar 19 -1,118,822 €2.47 €-2,761,674
X
Management checks
We assess Immutep's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Immutep has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company’s lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.

Details
Name: Immutep Limited
YP1A
Exchange: DB
Founded:
A$58,078,773
3,383,598,296
Website: http://www.immutep.com
Address: Immutep Limited
95 Pitt Street,
Level 12,
Sydney,
New South Wales, 2000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX IMM Ordinary Shares Australian Securities Exchange AU AUD 02. Jan 1992
OTCPK PRRU.F Ordinary Shares Pink Sheets LLC US USD 02. Jan 1992
DB YP1B Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
CHIA IMM Ordinary Shares Chi-X Australia AU AUD 02. Jan 1992
NasdaqGM IMMP SPON ADR EACH REP 100 ORD SHS Nasdaq Global Market US USD 17. Apr 2012
DB YP1A SPON ADR EACH REP 100 ORD SHS Deutsche Boerse AG DE EUR 17. Apr 2012
Number of employees
Current staff
Staff numbers
0
Immutep employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:03
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.